Clivatuzumab tetraxetan
Clivatuzumab tetraxetan (pronunciation: kli-va-TUZ-oo-mab tet-ra-XE-tan) is a radioimmunotherapy agent that is currently under investigation for the treatment of pancreatic cancer.
Etymology
The name "Clivatuzumab tetraxetan" is derived from the Latin clivus meaning "slope" or "hill", and tetraxetan, a term used in pharmacology to denote a four-branched molecule used in drug design.
Description
Clivatuzumab tetraxetan is a monoclonal antibody that is linked to a radioactive isotope, yttrium-90. The antibody targets a protein called MUC5AC, which is overexpressed in pancreatic cancer cells. The radioactive isotope then delivers a lethal dose of radiation to the cancer cells, while sparing healthy cells.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Radioimmunotherapy: A type of therapy that uses radioactive substances in combination with antibodies to treat cancer.
- MUC5AC: A protein that is overexpressed in pancreatic cancer cells.
- Yttrium-90: A radioactive isotope used in radioimmunotherapy.
- Pancreatic cancer: A type of cancer that starts in the tissues of the pancreas.
See Also
External links
- Medical encyclopedia article on Clivatuzumab tetraxetan
- Wikipedia's article - Clivatuzumab tetraxetan
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski